A subset (7% to 10%) of gastric gastrointestinal stromal tumors (GISTs) is notable for the immunohistochemical loss of succinate dehydrogenase (SDH) subunit B (SDHB), which signals the loss of function of the SDH complex consisting of mitochondrial inner membrane proteins. These SDH-deficient GISTs are known to be KIT/PDGFRA wild type, and most patients affected by this subset of GISTs are young. Some of these patients have germline mutations of SDH subunit genes SDHB, SDHC, or SDHD, known as Carney-Stratakis syndrome when combined with paraganglioma. More recently, germline mutations in SDH subunit A gene (SDHA) have also been reported in few patients with KIT/PDGFRA wild-type GISTs. In this study we immunohistochemically examined 127 SDHBnegative and 556 SDHB-positive gastric GISTs and 261 SDHBpositive intestinal GISTs for SDHA expression using a mouse monoclonal antibody 2E3 (Abcam). Cases with available DNA were tested for SDHA, SDHB, SDHC, and SDHD gene mutations using a hybridization-based custom capture next-generation sequencing assay. A total of 36 SDHA-negative GISTs (28%) were found among 127 SDHB-negative gastric GISTs. No SDHB-positive GIST was SDHA negative. Among 7 SDHA-negative tumors analyzed, there were 7 SDHA mutants, most germline. A second hit indicating biallelic inactivation of SDHA was present in 6 of those cases. These patients had no other SDH subunit gene mutations. Among the 25 SDHApositive, SDHB-negative GISTs analyzed, we identified 3 SDHA mutations (1 germline), and 11 SDHB, SDHC, or SDHD mutations (mostly germline), and 11 patients with no SDH mutations. Compared with patients with SDHA-positive GISTs, those with SDHA-negative GISTs had an older median age (34 vs. 21 y), lower female to male ratio (1.8 vs. 3.1) but similar mitotic counts and median tumor sizes, with a slow course of disease in most cases, despite a slightly higher rate of liver metastases. SDHA-negative GISTs comprise approximately 30% of SDHB-negative/SDH-deficient GISTs, and SDHA loss generally correlates with SDHA mutations.
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A small subset of gastric gastrointestinal stromal tumors (GISTs) (7% to 10%) has the loss of function of the succinate dehydrogenase (SDH) complex of the inner mitochondrial membrane. [1] [2] [3] [4] This complex of multiple proteins, all coded by chromosomal DNA, participates in the Krebs cycle and electron transport of oxidative phosphorylation and is normally ubiquitously present in mitochondria in all normal nucleated eukaryotic cells. 5 Loss of function of the SDH complex in these tumors is signaled by immunohistochemical loss of SDH subunit B (SDHB). SDHB-negative (SDH-deficient) GISTs comprise a great majority of gastric GISTs of children and young adults and a small portion of gastric GISTs in older adults. Although still incompletely understood, their oncologic pathogenesis is believed to be related to HIF1-a-mediated pseudohypoxia signaling triggered by succinate accumulation due to SDH loss and not to KIT/PDGFRA gain-offunction mutations, which are absent in these GISTs. [1] [2] [3] [4] Instead, the oncogenic signal in these tumors is likely mediated by activated insulin-like growth factor-1 receptor signaling as a consequence of HIF1-a overexpression. 1 A minority of patients with SDH-deficient GISTs have been found to harbor germline mutations of SDHB, SDHC, or SDHD, known as the Carney-Stratakis syndrome when combined with paraganglioma. 1, 6, 7 However, the mechanism of SDH protein losses in most cases of SDH-deficient GISTs remains unclear. Recently, a small number of GISTs have been found associated with germline loss-of-function mutations of SDHA gene encoding the key catalytic component of the SDH complex. 8, 9 Such mutations have been previously detected in an abdominal catecholamine-secreting paraganglioma. 10 In a patient with Leigh syndrome, a severe neurodegenerative disease, there was a compound heterozygous germline SDHA mutation (1 allele with nonsense and another with missense mutation). 11 A significant number of paraganglioma patients have mutations in the other SDH subunit genes, SDHB, SDHC, and SDHD. 12, 13 In this study, we report 36 SDHA-negative gastric GISTs among 127 SDHB-negative/SDH-deficient GISTs and examine SDHA and other SDH subunit gene mutations and pathology and prognosis of these tumors.
MATERIALS AND METHODS

Tissue Material and Immunohistochemistry
A total of 127 SDHB-negative (SDH-deficient) gastric GISTs were studied for SDHA expression using a primary mouse monoclonal antibody to SDHA (clone 2E3; Abcam, Cambridge, MA; diluted at 1:1000). Also tested were 556 gastric GISTs and 230 small intestinal and 31 colorectal GISTs positive for SDHB, determined immunohistochemically with a mouse monoclonal antibody 21A11 (Abcam; diluted at 1:1000). All immunostaining analyses were performed on a Leica BondMax autostainer (Leica Microsystems, Bannockburn, IL) using the Bond-Max avidin-biotin-free polymer-based detection system preceded by heat-induced epitope retrieval with Leica retrieval solution (high-pH buffer) for 25 minutes. Diaminobenzidine was used as the chromogen. All cases tested for SDHA and SDHB were validated as informative by showing a positive internal control (fibrovascular, lymphoid, smooth muscle, or mucosal elements). Immunohistochemistry for SDHA was analyzed blindly without knowing the SDHB expression or SDH subunit gene mutation status.
In addition, SDHB-negative GISTs with available material were evaluated for KIT (polyclonal antibody A4502; Dako Cytomation, Carpinteria, CA; diluted at 1:500), anoctamin1/DOG1 (monoclonal antibody, clone K9; Leica; diluted at 1:300), desmin (clone D33; Dako; diluted at 1:300), and CD34 (clone QBEnd/10; Dako Cytomation; diluted at 1:150), using a similar epitope retrieval and automation procedure as described above.
Smooth muscle actin (clone 1A4; Sigma Chemicals, St Louis, MO; diluted at 1:1000) was evaluated similarly but without epitope retrieval. All SDHB-negative tumors tested were positive for KIT (n = 125) and anoctamin1/ DOG1 (n = 80), and 87/111 cases were positive for CD34. Only 1/105 cases was focally positive for SMA.
Genetic Studies
DNA was obtained from microdissected formalinfixed, paraffin-embedded tumor tissue. SDH subunit genes SDHA, SDHB, SDHC, and SDHD were evaluated for mutations using a hybridization-based custom capture reagent (Agilent Inc., Santa Clara, CA), followed by sequencing on the GAIIx instrument (Illumina Inc., San Diego, CA) according to the manufacturer's protocols.
The Illumina raw sequence data were aligned with the Burrows-Wheeler Aligner against human genome hg19, and then variant calling was performed with the Samtools mPileup algorithm. The reference sequence for SDHA was NM_004168, for SDHB was NM_003000, for SDHC was NM_003001, and for SDHD was NM_003002. A subset of SDHA mutations was further validated by TaqMan assay (Invitrogen/Life Technologies, Carlsbad, CA). Mutations were verified as germline by showing their presence in normal tissue or peripheral blood, but in the absence of these tissues in some cases, the nature of mutations (germline vs. somatic) remained indeterminate. Comparative genomic hybridization was performed using a 180K feature array (Agilent) in selected cases to examine the copy number status of chromosome 5p, which includes the SDHA locus.
RESULTS
Pathology of SDHA-negative GISTs
A total of 36 of 127 gastric GISTs (28%) that were also verified as SDHB-negative (SDHB-deficient GISTs) were immunohistochemically SDHA negative (Table 1) . These cases showed granular cytoplasmic SDHA immunoreactivity only in the cellular components of the fibrovascular septa, lymphoid, or smooth muscle elements ( Fig. 1) .
Data on SDHA-negative GISTs are summarized in Tables 1 and 2 , and representative histologic images are illustrated in Figure 2 . SDHA mutations were detected in all 7 SDHA-negative tumors with available sequencing data, and 6 of them were germline mutations. Three of these were truncating mutations, 3 were missense mutations, and 1 a splice-site mutation ( Table 3 ). Six of these cases had a second hit in the SDHA locus: 3 loss of heterozygosity in the 5p15 region, 2 somatic mutations, and 1 5p deletion. There were no mutations in SDHB, SDHC, and SDHD in these patients. The tumor size varied from 1.2 to 21.5 cm (median, 5.0 cm). The mitotic rate varied from 0 to 26/50 HPF (median mitotic count, 4/50 HPF). Histologically typical of these tumors was multinodularity, often a plexiform muscularis propria involvement, and predominantly epithelioid hypercellular histology, as typically seen in the SDHB-negative (SDH-deficient) GISTs. A minority of cases showed spindle cell histology, usually as a focal finding. Marked nuclear atypia was detected in only 1 case, and no tumor showed overt coagulative necrosis. Peritumoral lymphovascular invasion was commonly detected (Fig. 2) .
Clinical Features of SDHA-negative GISTs
The clinical features are summarized in Table 2 . The patient group with SDHA-negative GISTs consisted of 23 women and 13 men of a median age of 34 years (range, 8 to 83 y). There were only 3 children less than 16 years of age, and 13 patients were older than 40 years. None of the patients were known to have neurological deficit syndrome, paraganglioma, or pulmonary chondroma.
Follow-up data were available for 20 patients ( Table 2) . Five patients were alive with no evidence of disease 8.5 to 17 years after first surgery, 8 were alive with liver metastases at 2 to 28.1 years, 4 died with liver metastases at 2.2, 3.3, 15.7, and 21.5 years, and 3 died of unrelated causes at 8 to 21 years.
SDHA-positive, SDHB-negative GISTs
A total of 91 of 127 (72%) SDHB-negative gastric GISTs retained SDHA and showed granular cytoplasmic positivity for SDHA, the normal pattern ( Fig. 3) . Twenty-five of these cases were available for mutation testing. Most (22/25, 88%) contained wild-type SDHA sequences. However, 3 patients had SDHA missense mutations, 1 of them germline (Table 3 ). Eleven patients had mutations in other SDH subunit genes, most of them germline: 5 in SDHB, 5 in SDHC, and 1 in SDHD (Table 3) . No SDH subunit mutations were detected in tumors from the remaining 11 SDHApositive cases tested.
These tumors did not significantly differ from SDHA-negative GISTs histologically, and they had similar median mitotic rate and tumor size, but there was a slightly higher percentage of tumors >10 cm ( Table 2) . Of the 59 patients with follow-up, 33 were alive without disease 1.5 to 42 years (median, 16.3 y), 16 were alive with disease (most with known liver metastases) 2 to 43 years (median, 8.8 y), and 9 died of disease 1.5 to 35.6 years after first surgery (median survival, 8.8 y). One patient died of unrelated disease 15.7 years after first surgery. Four patients also had paragangliomas, and 1 of these patients had an SDHB mutation and therefore fulfilled the criteria of Carney-Stratakis syndrome. Two others had pulmonary chondromas (Carney triad).
All 433 gastric, 53 duodenal, 177 small intestinal (jejunal/ileal), and 31 colorectal SDHB-positive GISTs were SDHA positive.
DISCUSSION
In this study, we examined the frequency, genetic correlation, and clinicopathologic features of gastric GISTs with immunohistochemical SDH subunit A (SDHA) loss. These tumors form a subgroup of SDHB-negative (SDHdeficient) GISTs comprising 28% (36/127) of all such cases in our patients. Like other SDHB-negative GISTs in general, SDHA-negative GISTs are restricted to gastric location, and they have a predilection to young patients, although they are less common in children and have a higher patient median age.
As an immunohistochemical marker, SDHA is analogous to SDHB. For practical interpretation, it is critical to observe the presence of immunoreactivity in nonneoplastic components to validate the immunostaining as technically adequate. The general principle in interpretation of a negative result is to observe a contrast between the negative tumor and the positive internal control: cellular components of the fibrovascular septa, smooth muscle, lymphoid, or epithelial elements. Most cells retaining SDHA show granular cytoplasmic immunostaining consistent with the mitochondrial location of this antigen.
Considering that SDHB loss destabilizes the SDH complex rendering it nonfunctional 12, 13 and that A subunit is anchored by subunit B, 5 it is somewhat unexpected that SDHA expression is still retained in a majority of cases with SDHB loss. However, the immunohistochemical presence of SDHA, the main catalytic unit of SDH, 5 does not mean that this subunit is functional. Also, the complex is anyway nonfunctional with the loss of SDHB, the iron sulphur protein participating in electron transfer of oxidative phosphorylation.
There was a strong correlation between immunohistochemically observed loss of SDHA and SDHA mutations, which was detected in all 7 patients analyzed, whereas present only in 3 of 25 patients with SDHApositive, SDHB-negative GISTs. In contrast, none of these patients with SDHA-negative GISTs had SDHB, SDHC, or SDHD mutations. Therefore, SDHA mutations (mostly verified as germline here) are the apparent cause for SDHA loss and destabilization of the SDH complex, especially because biallelic changes with losses or somatic mutations in the SDHA locus were common and detected in most cases in this study. A previous study also showed SDHA germline mutations coupled with somatic SDHA mutations in the tumor in some cases. 9 Therefore, these SDHA alterations seem to follow a classic 2-hit hypothesis of tumor suppressor genes, as has been previously found for other SDH subunit gene mutations in paragangliomas. 12, 13 Both truncating and missense SDHA germline mutations were associated with the loss of protein The unmarked cases in the column headed "Germline mutations" are indeterminate for whether they are somatic or germline. * indicates stop codon expression. This is not surprising in view of most SDH subunit loss-of-function mutations in SDHB-negative paragangliomas also being missense mutations. 14 Loss of function has also been resulting from missense mutations in other tumor suppressor proteins, such as merlin, the NF2 gene product in schwannoma, and TSC1 in transitional cell carcinoma. On the basis of those studies, such missense mutations are deleterious causing protein instability and premature degradation. 15, 16 Abnormal trafficking of subunit proteins or problems in assembly of the SDH complex containing 1 mutant protein could be additional explanations. Immunohistochemical loss of SDHA can pinpoint an SDHA germline mutation in most cases, but a minority of such mutant proteins seems to retain immunoreactivity. Therefore, mutation analysis will be necessary to definitively determine SDHA mutation status and type, but detection of SDHA loss allows focusing the mutation analysis specifically to the SDHA gene. Although detection of an SDHA germline mutation may not have an immediate clinical significance, its presence raises the question of the need for family studies and associated genetic counseling. It may also become a factor in treatment selection in the future. SDHB negativity in GIST is not effective in determining the specific SDH genotype, as SDHB expression is lost after the loss of any SDH subunit proteins, on the basis of our studies and the previous ones in paragangliomas. 12, 13 According to our observations, SDHA mutations in SDHB-negative (SDH-deficient) GISTs seem to be as common as other SDH subunit mutations together. However, SDHA is the only mutated subunit gene in SDHA-negative GISTs. A caveat in the comparison of the relative frequencies of SDH subunit gene mutations is that large deletions can escape detection in our custom capture mutation search. Although such deletions have been reported in paraganglioma patients, they are a minority among all SDH mutations and have not been reported in SDHA (TC Cycle Gene Mutation Database). 14 There are some clinicopathologic differences between SDHA-negative and SDHA-positive, SDHB-negative (SDH-deficient) GISTs. SDHA-negative gastric GISTs are rare in children and have a later onset and a lesser female predominance than SDHA-positive, SDHB-negative GISTs. They have similar mean tumor sizes and mitotic rates but a slightly lower frequency of tumors >10 cm. Both groups have a slow course of disease with a relatively low rate of mortality (15% to 20%), but patients with SDHA-negative tumors seem to have a higher frequency of liver metastasis. However, the number of cases is small, thus definitive assessment of the possible prognostic difference requires additional data. Even patients with liver metastases often survive for years with a slow, if any, disease progression, as is known for SDHB-negative GISTs in general; thus appearance of liver metastasis is not necessarily a relevant endpoint in prognostic analysis for these patients. To what extent this long survival with metastases is a factor of given targeted and other new therapies is unknown. However, our groups were not biased for any particular treatment regimen. A previous study of SDHB-negative GISTs found that 7 of 66 patients died of disease in long-term follow-up. 4 Paraganglioma does not seem to be as commonly associated with SDHA-negative as with SDHA-positive, SDH-deficient GISTs, and pulmonary chondromas were not detected, thus none of the patients with SDHAnegative GISTs fulfilled the criteria of Carney-Stratakis syndrome or Carney triad.
In summary, we detected immunohistochemical loss of SDHA in 28% of patients with SDHB-negative GISTs. This loss was associated with SDHA germline mutations and unassociated with any other SDH subunit gene mutations. Therefore, immunohistochemical analysis of SDHA expression may indirectly assist in SDH genotyping. Compared with other SDH-deficient GISTs, SDHA-negative GISTs occur in older patients and have a lesser female predominance, but they seem prognostically essentially similar to the other SHD-deficient GISTs. Further studies are needed to establish the biological correlation and clinical significance of these findings.
